Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Notes Payables (2016 - 2018)

Lisata Therapeutics (LSTA) has disclosed Notes Payables for 9 consecutive years, with $23289.0 as the latest value for Q2 2018.

  • For the quarter ending Q2 2018, Notes Payables fell 95.97% year-over-year to $23289.0, compared with a TTM value of $23289.0 through Jun 2018, down 95.97%, and an annual FY2017 reading of $159000.0, down 77.29% over the prior year.
  • Notes Payables was $23289.0 for Q2 2018 at Lisata Therapeutics, down from $92048.0 in the prior quarter.
  • Across five years, Notes Payables topped out at $2.1 million in Q2 2015 and bottomed at $23289.0 in Q2 2018.
  • Average Notes Payables over 5 years is $961723.9, with a median of $995576.0 recorded in 2014.
  • The sharpest move saw Notes Payables surged 1085.46% in 2014, then tumbled 95.97% in 2018.
  • Year by year, Notes Payables stood at $1.6 million in 2014, then tumbled by 31.25% to $1.1 million in 2015, then tumbled by 36.36% to $700000.0 in 2016, then tumbled by 77.29% to $159000.0 in 2017, then tumbled by 85.35% to $23289.0 in 2018.
  • Business Quant data shows Notes Payables for LSTA at $23289.0 in Q2 2018, $92048.0 in Q1 2018, and $159000.0 in Q4 2017.